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Abstract 
The primary challenge to promulgating a more human-centred approach to managing and 
accounting for innovation is: can we encourage innovation that adds net social value? At the 
same time, can we deter - or at least not encourage - innovation that serves malicious ends, or 
that poses grave threats to humanity? Therefore, the aim of this paper is to obtain answers 
concerning bionanotechnology as a research field, but which are their applications? What sort 
of ethical and moral dilemmas encompasses? And, does the level of such dilemmas is a sum 
of biotechnology and nanotechnology, or imposes new challenges? 
 
Introduction 
Innovation traditionally was viewed as a linear process: from basic research value to 
technology development and on to test/evaluation, demonstration, deployment, 
commercialization, and ultimately, market penetration. And perhaps, if successful, market 
saturation, obsolescence, and finally replacement. Human (and social) factors- needs, desires, 
demands, behaviour - were considered either not at all or intuitively, anecdotally, 
coincidentally, mechanically, and often reactively. Innovation was driven, first, by hard 
science, engineering, and production, with marketing and sales trailing behind like army camp 
followers. 
The key challenge to disseminate a more human-centred approach should manage and 
account for innovation net social value. That is, whose benefits clearly outweigh its costs?; at 
the same time, can we dissuade innovation that serves malicious ends or that poses grave 
threats to mankind? In that sense, such challenge is clearly bounded to the field of 
bionanotechnology. But, how can we define bionanotechnology? As we will demonstrate, 
such concept is still an ongoing debate, and for that we need to address two levels of arguing: 
• what is biotechnology? Which are its applications? What ethical and moral dilemmas 
arise? 
• what is nanotechnology? Which are its applications? What ethical and moral 
dilemmas arise? 
 
Biotechnology can be broadly defined as using organisms or their products for commercial 
purposes. It has been used into food, crops or domestic animals; but, recent developments in 
molecular biology have given biotechnology a new meaning, a new prominence, and a new 
potential. It is (modern) biotechnology that has captured the attention of the public, and of 
course encompasses a great deal of ethical and moral dilemmas, as the ones related to 
healthcare. 
Nanotechnology is the creation of functional materials, devices, and systems through control 
of matter on the nanometer length scale, the exploitation of novel properties and phenomena 
developed at that scale. Through out literature it is possible to find several examples of 
nanotechnology applications: giant magneto resistance in nanocrystalline materials, 
nanolayers with selective optical barriers, etc. (IMM, 2003). Concerning the possible and 
moral dilemmas of such technology it is usual that philosophers, ethicists and many scientists 
frequently speak as such objects will exist in the very near future, but in fact they already 
exist which clearly creates a policy vacuum. 
Only after the previous analysis is possible to acknowledge the objective of our paper: how 
can we define bionanotechnology as a research field? Which are its purposes? What kind of 
ethical and moral dilemmas occur? And, does the rank of such dilemmas correspond to a sum 
that elapses from biotechnology and nanotechnology, or imposes new challenges? 
 
Development 
Biotechnology and its applications 
Contrary to its name, biotechnology is not a single technology. Rather it is a group of 
technologies that share two common characteristics: working with living cells and their 
molecules; and, having a wide range of practice uses that can improve our lives. In spite of 
such claim, we will plead that biotechnology is unique amongst the three major technologies 
for the twenty-first century - information technology, materials science, and biotechnology - 
because is a sustainable technology based on renewable biological resources. Such natural 
resources include animals, plants, yeasts, and microorganisms and having formed mankind’s 
nascent food and beverage industry for several millennia. 
So, biotechnology can be broadly defined as “using organisms or their products for 
commercial purposes” (NAL, 2008). But recent developments in molecular biology have 
given to biotechnology a new meaning, a new prominence, and a new potential. It is this 
(modern) biotechnology that has captured the attention of the public, which has a dramatic 
effect on the world economy and society. 
Historically, the modern era of scientific biotechnology commenced with the elucidation of 
the DNA structure by Watson and Crick in 1953, and the subsequent development of the tools 
to cleave and resplice genetic material in the early 1970s. Not surprisingly, therefore, the term 
biotechnology is generally considered synonymous with gene splicing and other forms of 
genetic engineering. 
However, in the future, the most significant breakthroughs in human medicine will result 
from mapping and understanding the human genome. With less than five per cent of all 
human genes identified, it has become increasingly clear that each new gene discovery 
proffers new drugs for the diagnosis, treatment, and prevention of human disease (OECD, 
2002). These advances will enable biotechnologists not only to measure disease potential and 
expand the applications for genomic diagnostics, but also to devise fundamental new 
therapeutic approaches. Products and medical applications of modern biotechnology include: 
artificial blood vessels from collagen tubes coated with a layer of the anticoagulant heparin 
(Dyck et al., 1999; Huynh et al., 1999); and, gene therapy (altering DNA within cells in an 
organism to treat or cure a disease) is developing therapies to treat diseases such as cystic 
fibrosis, AIDS and cancer (BIO, 2005). 
Genomics and genetic engineering are also playing a substantial role in the development of 
agricultural biotechnology. The early goals in the development of transgenic livestock were 
the increase of the meat and the production characteristics of food animals. However, long 
research and development timelines associated to low projected profit margins, especially in 
developed nations where food is relatively inexpensive; have shifted priorities to the 
production of protein pharmaceuticals and nutraceuticals in the milk of transgenic animals 
(Lowe, 1999). And, similar initiatives using genetic manipulation are aimed at making crops 
more productive by reducing their dependence on pesticides, fertilizers and irrigation, or by 
increasing their resistance to plant diseases (Lowe, 1999). 
Plus, marine organisms are also capable of producing a variety of polymers, adhesives, and 
compounds for cosmetics and food preparation. Bioactive natural products are found in 
organisms that reside in areas which stretch from easily accessible intertidal zones to depths 
in excess of 1000 meters. Collaborations between marine chemists, molecular 
pharmacologists, and cell biologists have yielded an impressive library of potentially use 
(NAL, 2008). However there are still many catalysts still to be discovered, which will have to 
exhibit improved performance, stability, turnover numbers, specificity, and product yields. 
Biotechnology is also playing a role in clean manufacturing. Nevertheless, various types of 
chemical manufacturing, metal plating, wood preserving, and petroleum refining industries 
currently generate hazardous wastes, comprising volatile organics, chlorinated and petroleum 
hydrocarbons, solvents, and heavy metals. Bioremediation with microbial consortia is being 
investigated as a means of cleaning up hazardous sites. Methods include in situ and ex situ 
treatment of contaminated soil, groundwater, industrial wastewater, sludge’s, soil slurries, 
marine oil spills, and vapour-phase effluvia. 
Finally, biotechnology is being currently used in DNA fingerprinting (process of cross 
matching two strands of DNA) namely into the following fields (BIO, 2005): 
• criminal investigations- DNA from samples of hair, bodily fluids or skin at a crime 
scene as a way to confirm suspects is enhancing rapidly; 
• polymerase chain reaction (PCR)- process that entails into a more quick and accurate 
way of identify the presence of infections such as AIDS, Lyme disease and 
Chlamydia; 
• paternity determination- through DNA it is possible to confirm if a child’s DNA 
pattern is inherited, half from the mother and half from the father; 
• human fossils- to determine how closely related fossil samples are from different 
geographic locations and geologic areas. The results shed light on the history of 
human evolution and the manner in which human ancestors settled different parts of 
the world. 
 
The ethical dimensions of biotechnology 
The ethical issues created by biotechnology are vast and growing. Our present moral systems 
work mightily to reconcile the new world order into their established patterns of accepted 
behaviour. The ethics of biotechnology raises immensely complex issues; the biotechnology 
of ethics raises even more intractable ones. Our current scientific advances promise to allow 
us to engineer the most basic of our life processes: the dissemination in our environment of 
genetically modified organisms (GMO); the genetic modifications and their use in food; the 
applications of research in human genetics. 
The publication of the first experimental protocols of the technique of genetic engineering in 
1973 (on micro-organisms) raised the fear into researchers: many biologists considered it was 
a high risk activity, and therefore restrictive measures were taken. The GMOs had to be 
confined and prevented from disseminating in the environment. They could modify the 
“balance of nature” and subsequently the foreign DNA could alter the metabolic activity in an 
unpredictable and undesirable way, producing unsuspected and irreparable damage to 
environment and mankind. In fact, science fiction literature was already starting the debate by 
presetting GMOs with the ability to destroy the reserve of raw materials, enhancing the lack 
of confidence concerning such organisms. 
With new progress in scientific knowledge and experimental techniques, it occurred to 
scientists not to confine the GMOs in bioreactors, but to let these organisms grow freely in the 
soil in order to improve: the environment through micro-organisms with the ability to clean 
chemically contaminated soils (bioremediation); and, the performance of vegetal culture. 
However, such decisions entail into a discussion regarding the relationships between these 
GMOs and other organisms (including human beings). Won’t the modified characteristics be 
transferred to other organisms, creating non intentional and, may be, damageable effects 
(OECD, 2005)? Our knowledge about the interactions between the microbial populations in 
an ecosystem is fragmentary, especially on the exchange of genetic material, but precise 
studies are going on (BIO, 2005). No negative effects of the release of GMOs (micro-
organisms) have been reported until now; however studies are being conducted (BIO, 2005). 
The problem is to know if they can be set up with objectivity. The question remains open: can 
this problem be treated with objectivity, similar to debate regarding nuclear power? 
Biotechnology may soon provide us with the ultimate ability to “design” our individual moral 
senses and biologically “grow” implanted ethical codes of behaviour within the human being. 
The more commanding focus will be on the genetics of ethics, rather than on the ethics of 
genetics. 
Therefore, we need to recognize the extraordinary uniqueness of current life forms and how 
highly special and precious they remain. To the extent, modern science threatens the delicate 
symbiosis between our ethical and legal norms and our biological evolution. New, daily 
scientific advances leave a moral order ill-equipped to respond. Ethical choices are the result 
of deeply ingrained predispositions and a lifetime of cultural adaptation. When faced with 
new situations, we tend to respond slowly, viewing any significant departure from the moral 
status quo as a threat. The law also inherently moves slowly, proceeding through careful 
analysis and studied reflection. Legal precedent and a hierarchical judicial system lend 
additional brakes to an already sluggish, orthodox order. 
With such intrinsic conservatism, it should come as no surprise that we are today continuing 
to struggle, both ethically and legally, with technological breakthroughs that are decades old. 
Contraception and abortion are, at their core, denials of our biological selves (Singer, 1981; 
Dawkins, 1989; Thiele, 1999) and, thus we continue to be uncomfortable with the 
ramifications inherent in the utilization of the technology. Contraception is still vigorously 
debated in many societies, through technology that is now antiquated. 
Currently, biotechnology among many other things is enabling us to begin prenatal testing for 
fetal genetic conditions and to begin artificial manipulation of an unborn’s genotype. The 
intractable social, moral, and legal issues posed by only these two technological advances 
illustrate the potential impact of biotechnology in our society (Kevles, 1993; 1995). When is 
such testing viable and to whom should it be made available? Which genetic disorders or 
diseases will allow (require?) state regulated abortions or invasive procedures? How are the 
rights of a “good-gene” child to be weighed against maternal health and reproductive 
freedom? Who should bear the economic costs of raising a child conceived with certain 
knowledge of the genotype-disorder? Is there a duty for individuals to test in vitro so they 
may reject embryos that pose significant health costs over the embryo’s lifetime? What is a 
“bad” gene trait and how do we decide which embryos are “good” (Burgess, 2001)? What 
will happen at an ethnical level: will nations be characterized by homogeneous ethnic groups, 
encompassing therefore synonymous cultures (Brunger and Bassett, 1998)? Of greater 
concern is the short shrift paid to concerns about biopiracy in isolated communities (Burgess, 
2001). 
Moreover, all these dilemmas entail into an important discussion regarding biotechnology 
patents: it is possible for a company or a country owns our genetic evolution, instead of 
mankind itself? In fact, there is a substantial debate in public forums and academic circles 
about whether patenting is morally and ethically acceptable (see for example: McGee, 1998; 
Caplan, 1998; Merz and Cho, 1998; Caulfield and Gold, 2000; Gold, 2000). Regarding such 
matter, we will assume the vision underline by Caulfield and Gold (2000), which entails into 
the absence of patents regarding the human genome. 
Clearly, all the previous questions remind us the importance of undertaking a critical 
reflection concerning the role of industry into biotechnology, as Rahul Dhanda (2002) in this 
well-written book, “Guiding Icarus: Merging Bioethics with Corporate Interests” explores. 
Dhanda makes it clear at the outset that he is an industry insider, working for Interleukin 
Genetics, and so his perspective is explicitly pro-science and pro-industry. Therefore, he is not 
naive about the many pitfalls of industry or the social responsibility that it bears. Even if you 
disagree, as we do, with some elements of Dhanda's position regarding the following issues: 
• the critical importance of comprehensive informed consent procedures- such 
procedures are not only hints at the real problems with how informed consent is used 
(as a paper to sign rather than as an ongoing process), which undermines its protective 
utility; 
• the insufficient attention to whether DNA donors- such people are likely to understand 
what they are consenting to; 
• the DNA databases- as it occurs in any database, DNA databases can also produce 
errors and be violated, which means a blind faith in them will lead people to discount 
the possibility that their personal DNA information can be wrong; 
• the DNA patents- it should not be allowed to any company to patent the human 
genome, in spite of the valid economical argument concerning the costs of research. 
 
He is still convincing about the need to integrate bioethics as a corporate value within the 
biotechnology industry. In conclusion, such questions guarantee many decades of ethical and 
legal wrangling. We are living beings designed to forward our biological selves; when 
technology changes the landscape too quickly, we tend to become confused and resist what 
are often perceived as threats to our self-identity. Technological interference with, or 
enhancement of, natural processes is, simply, something that frustrates us. And while we are 
attempting to resolve the momentous issues raised, technology speeds ahead leaving a 
perplexed and somewhat paralyzed society in its wake. 
 
Nanotechnology and its applications 
Nanotechnology emerged as an important research area in the 1980s. From the beginning, 
nanotechnology has been observed to be an enabling, horizontal, and cross-sectoral 
technology (Franks, 1987). It is projected to revolutionize several industrial sectors by 
providing valuable technological innovations, but before define such research field it is 
important to address the etymology of the concept “nano”. The Greek word nanos (dwarf) is 
the origin of nano; meaning that a nanometer is one billionth of a meter, or roughly 75,000 
times smaller than the width of a human hair. Therefore, approximately three to six atoms can 
fit inside of a nanometer (nm), depending on the atom. 
When Drexler coined the word nanotechnology in the 1980s, he was discussing about 
building machines on the scale of molecules, a few nanometers wide-motors, robot arms, and 
even whole computers, far smaller than a cell (Drexler, 1986). Drexler spent the next ten 
years describing and analyzing these incredible devices, and responding to accusations of 
science fiction. Meanwhile, mundane technology was developing the ability to build simple 
structures on a molecular scale. As nanotechnology became an accepted concept, the meaning 
of the word shifted to encompass the simpler kinds of nanometer-scale technology, as 
described in another book of Drexler (1991), called the “Unbounding the Future”. In fact, the 
importance of Drexler into the research field is also recognized through the foundation of the 
Foresight Institute, which is a nonprofit organization dedicated to the responsible 
development of nanotechnology (FI, 2000). However, this theoretical capability was 
envisioned in 1959 by the renowned physicist Richard Feynman in his lecture, “There’s 
Plenty of Room at the Bottom”, concerning miniaturization down to the atomic scale. 
Applications of nanotechnology extend to several fields, following four generations of 
nanotechnology development (Roco, 1998; Roco, 2001; Roco, 2001a; Roco, 2001b; Roco, 
2002; Roco, 2003): 
The present era, as Roco illustrates it, concerns passive nanostructures, materials designed to 
perform one task. The second phase, started around 2005, and introduced active 
nanostructures for multitasking. The third generation is expected to begin emerging around 
2010 and will feature nanosystems with thousands of interacting components. After that, a 
few years later it will arise the first integrated nanosystems, similar to a mammalian cell with 
hierarchical systems within systems, are expected to be developed. 
For instance, examples of nanotechnology generations in biomedical and biotechnology are: 
targeted drug delivery, gene therapy, and nanomedicine (biomechatronic human prostheses 
for locomotion, manipulation, vision, sensing, and other functions, such as: artificial limbs, 
artificial internal organs, artificial senses, human augmentation) (Davis, 1997; West and 
Halas, 2000; Bogunia-Kubik and Sugisaka, 2002). This field has important connection with 
neuroscience, to develop neural interfaces and sensory motor coordination systems for the 
integration of these bionics devices to human body/brain. In the field of computing it is 
possible to acknowledge: nano-computers and defect tolerant computer architectures (Heath, 
et. al., 1998). In the field of microelectronics we have the following examples: the 
replacement of silicon with carbon nanotubes in a transistor (McEuen, 1998); miniaturization 
of electronic devices (Sohn, 1998); and, DNA-based computing (Seeman, 1998). These 
advances have taken place with parallel advances in methodologies and instrumentation such 
as scanning tunnelling microscopy (Quate, 1991). 
Finally an important question arises: why is the length scale of nanotechnology so important? 
According to the LANL (2008), there are five reasons: the wavelike properties of electrons 
inside matter are influenced by variations on the nanometer scale. By patterning matter on the 
nanometer length scale, it is possible to vary fundamental properties of materials without 
changing their chemical composition; the systematic organization of matter on the nanometer 
length scale is a key feature of biological systems; nanoscale components have very high 
surface areas, making them ideal for use in composite materials, reacting systems, drug 
delivery, and energy storage; the finite size of material entities, as compared to the molecular 
scale, determine an increase of the relative importance of surface tension and local 
electromagnetic effects, making nanostructured materials harder and less brittle; the 
interaction wavelength scales of various external wave phenomena become comparable to the 
material entity size, making materials suitable for various opto-electronic applications. 
 
The ethical dimensions of nanotechnology 
With such awesome potential dangers inherent in nanotechnology, we must seriously examine 
its potential consequences. Granted, nanotechnology may never become as powerful and 
prolific as envisioned by its evangelists, but as with any potential, near-horizon technology, 
we should go through the exercise of formulating solutions to potential ethical issues before 
the technology is irreversibly adopted by society. We must examine the ethics of developing 
nanotechnology and create policies that will aid in its development so as to eliminate or at 
least minimize its damaging effects on society (Sweeney, Seal and Vaidyanathan, 2003). 
However, the ethical implications of nanotechnology are simultaneously unpredictable and 
predictable. 
In his novel The Nanotech Chronicles, Michael Flynn (1991) presents his view on the gradual 
development of future nanotechnology and its social implications through out six nano-
science fiction stories, which can provide us some interesting directions regarding such 
matter. However, we tend to disregard that the ethical perception concerning biotechnology 
can be a good starting point for the ethical implications of nanotechnology, as suggested by 
Weil (2001), or Wolfson (2003). Moreover, the principles that Richard Severson (1997) 
outlines in his book, “The Principles of Information Ethics”, to guide IT ethical decisions are 
also insufficient to this analysis. In our opinion, the ethical analysis concerning 
nanotechnology should engage the implications link between: individual level; professional 
level; and, societal level. 
Nanotechnology as a tremendous impact on individual identity because the ethical concept of 
life revolves around nanotechnology in accordance to Venneri (2001, 234): “nanotechnology 
encompasses the attributes of self-generation, reproduction, self-assembly, self-repair and 
natural adaptation”, and clearly these are all attributes we ascribe to living things. The other, 
fantastic aspect of how the concept of life might change with nanotechnology regards the 
promises of nanomedicine. Nanotechnology may be able to repair or reproduce tissue, 
diagnose disease (e.g. cancer) at a very early stage, dispense drugs at the cellular level, and 
even reverse disease. Therefore, our concept of the human life span may be revolutionized as 
a result; people may live longer by techniques considered by many to be artificial. Some will 
wonder if nanotechnologists are “playing God” by tinkering so directly with nature. Others 
will wonder to what extent humanity and nanomachinery will blend; if we are downloaded 
into our technology, what are the chances that we will thereafter be ourselves or even human 
(Joy, 2000; Weckert, 2001)? 
Plus, future nanotechnology-enabled, implanted or swallowed diagnostic tools will make 
possible the collection of an enormous amount of individual cellular/subcellular level 
surveillance data of the human body, which is remotely transmitted to a medical database 
server to be analyzed and monitored by diagnostic software. When such technologies become 
possible, a key ethical question arises: can the health information infrastructure handle, 
collect, process, and analyze real-time on-going health data? Moreover, ensuring privacy and 
confidentiality in such a system would be of utmost importance; a system without adequate 
safeguards presents serious ethical problems. 
From the above it is clear that an in-depth ethical analysis is necessary having in 
consideration the human dignity through the following requirements (UNESCO, 2006) 
• non-instrumentalisation- the ethical requirement of not using individuals merely as a 
means but always as an end of their own; 
• privacy- the ethical principle of not invading a person’s right to privacy; 
• non-discrimination- people deserve equal treatment, unless there are reasons that 
justify difference in treatment. It is a widely accepted principle and in this context it 
primarily relates to the distribution of health care resources; 
• informed consent- the ethical principle that patients are not exposed to treatment or 
research without their free and informed consent; 
• equity- the ethical principle that everybody should have fair access to the benefits 
under consideration; 
• the precautionary principle- this principle entails the moral duty of continuous risk 
assessment with regard to the not fully foreseeable impact of new technologies as in 
the case of ICT implants in the human body. 
 
At a professional level nanotechnology can raise the following issues to its practitioners 
(Flynn, 1991): the dimensions of intended and unintended social consequences of 
technological innovation, including attempts to fix unintended consequences by technological 
implementation, and cultural conservatism; understand the limits of social foresight and of 
planning technology-induced social changes; the different kinds of interests and values that 
professionals are confronted and the need for responsible decisions; risk analysis and the 
social relativity of risk perception; standard excuses from moral responsibility. 
Finally, at a societal level we may refer that nanotechnology embraces potential dangerous for 
the environment. In 2002, researchers reported to the Environmental Protection Agency 
(EPA) that nanoparticles have appeared in the livers of research animals and that there is a 
potential for nanoparticles to piggyback on bacteria and enter the food chain. There is no 
regulatory body that is tracking nanomaterials, so we could be releasing an undetectable toxin 
into the biosphere (Rupley, 2002). However, the ethical dilemmas are far more complex that 
the environmental issues. 
An essential feature that sets nanostructures apart from other artefacts is size. They are from 
1 to 100 nanometers, from one- to 100-billionths of a meter, significantly less than the 50,000 
nanometers of a human hair. Obviously, they cannot be perceived by the naked eye (Ratner 
and Ratner, 2003: 6), and can thus be produced and deployed without ever being observed by 
any human being. The kinds of ethical issues this unobservability creates can be illustrated by 
noting three problems: privacy; intrusion; disclosure and appropriation. These problems are 
external to nanotechnology. They arise through what are predictably the ordinary uses made 
of nanostructures or as a consequence of there being nanostructures at all. 
Concerning privacy, we could simply add nano-sensing devices to the paint or a composition 
floor to turn a ‘safe’ room into a recording and transmitting studio. Alternatively, such 
devices could be put into our bodies without our being the wiser. The average citizen would 
be at the complete mercy of anyone familiar with nano-sensing. Their detection would 
require what we can presume to be special highly sophisticated equipment (Robison, 1994: 1-
2). 
We are also helpless to preclude disclosure, the second privacy tort. The standard sort of 
example is someone’s passing on a secret. The secret is disclosed. We all keep some 
information to ourselves. This is, among other things, one way of distinguishing between 
friends, acquaintances and strangers. We tell friends things about ourselves that would be 
inappropriate to tell our acquaintances (although that would be one way of beginning to turn 
an acquaintance into a friend). Telling such things to strangers would mark us as addled, if 
not crazy. Control over information about our personal lives allows us to keep, among other 
things, control over who we are: publicly, and privately. Nanosensors would allow a stranger 
to know everything about us that we would want to control, from private conversations with 
one’s spouse or lover to intimate details about one’s body temperature and state of health. A 
stranger could well know far more about us than we can know about ourselves (Robison, 
2004). 
That someone knows as much or more about us as we do permits the last relevant privacy 
tort, namely appropriation. That occurs when someone takes another’s identity. Such theft 
will become that much easier as information about us is relayed to a stranger who will pick 
up all those conversations we think are private, and use that information to appropriate our 
identity (Robison, 2004). 
In each case- intrusion, disclosure and appropriation- our privacy is invaded, and of course 
such invasion can obviously also be harmful, which is enhance by nanotechnology. 
 
Bionanotechnology and its applications 
After the debate concerning biotechnology and nanotechnology, how can we define 
bionanotechnology as a research field? At the present time, there is no consensus definition of 
bionanotechnology. To take advantage of the enthusiasm of funding agencies, a number of 
old (and important) areas, such as colloid science, molecular biology, and implantable 
materials surface science, have been relabelled nanotechnology. In fact, all of these fields 
coupled with biological systems, should be included in bionanotechnology. Therefore, the 
idea of bionanotechnology embraces the engineering of interfaces between molecules or 
materials and biological systems, which clearly encompasses a wider, or a blurred definition. 
Even acknowledging the following definitions the quandary holds: “bionanotechnology 
claims that it is a multi-disciplinary area that sits at the interface between engineering and the 
biological and physical sciences” (BBSRC, 2007: 1); while the OECD defines it as “an area 
that covers the interface between physics, biology, chemistry and the engineering sciences” 
(OECD, 2005:4); or, “bionanotechnology represents the convergence of nanotechnology and 
biotechnology, yielding materials and products that use biological molecules in their 
construction or are designed to affect biological systems”(NCBC, 2007: 3). Some examples of 
bionanotechnology applications include: engineering biomolecules for non-biological use, 
such as DNA-based computer circuits using nanotechnology tools; medical diagnostic devices 
and medical imaging to study biology combining nanomaterials with biological systems for 
outcomes such as targeted drug therapies. 
However, despite the political rhetoric and normative discourses that claim the prospective of 
such technology, due to immeasurable institutional inflexibility (insecure career paths, unfair 
evaluation, need of longer training), the truth is that the conventional wisdom concerning its 
benefits is not supported by systematic evidence and remains poorly understood (Weingart 
and Stehr, 2000; Bruce et al., 2004; Schild and Sorlin, 2005). Although since the 1990s there 
has been an outstanding output of new empirical studies to add to the more plentiful 
conceptual and normative approaches adopted in the past, where a worrying lack of consensus 
about how to measure cross-disciplinarity arise (Bordons, Morillo and Gómes, 2004). Another 
crucial aspect that still needs to be evaluated is the costs and risks of failure regarding its 
ethical and moral dilemmas. 
 
Conclusion 
Through out this paper we have acknowledged the arguments that allow us to reveal the 
answers regarding biotechnology and nanotechnology. Plus, we were able to respond to the 
primary research question: how can we recognize bionanotechnology as a research field? 
However, the literature review process seems to disregard the answers regarding its ethical 
and moral dimensions. Such reality induces us to argue through our personal opinion 
concerning such matter: bionanotechnology encompasses not only the ethical dilemmas that 
prevail in each one of the research fields, biotechnology and nanotechnology, but enhanced 
such dilemmas. 
The key reason for our argument is simple, and probably debatable; however, in order to 
justify our argument we present two valid assumptions: bionanotechnology as a research field 
is still an unknown variable, as well as it is boundaries. In fact, even the scientific community 
disagrees about the concept itself - as demonstrated above; and, the ethical and moral 
dilemmas that biotechnology and nanotechnology engage are still under debate, and may be 
considered blurred or fuzzy. Therefore, the ethical and moral dilemmas of bionanotechnology 
can be considered as a Pandora box. 
In conclusion, a research field that elapses from an ongoing definition, and whose ethical and 
moral dilemmas is a composite of the previous ones, clearly enhances the existent ethical 
quandaries. 
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